Cutaneous T-cell lymphoma (CTCL) is a form of non-Hodgkin lymphoma that may develop over many years and can become resistant to standard therapy. The purpose of this study is to compare the effectiveness of an investigational drug called KW-0761(mogamulizumab) with an established drug for CTCL called vorinostat in patients with CTCL that has persisted despite standard therapies. KW-0761 is an antibody that targets a protein on CTCL cells called CCR4.
Patients will be randomly assigned to receive KW-0761 or vorinostat. Patients whose CTCL continues to grow while on vorinostat may have the option of receiving KW-0761 instead. KW-0761 is given intravenously (by vein), while vorinostat is taken orally (by mouth).